FEATURE ARTICLES
The ingenuity on display went well beyond the latest equipment. From technological innovation and operational excellence to sustainability and supply chain solutions, the FOYAs celebrated how facility design brings these pieces together to create a superior working environment.
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- Capturing Tablet Disintegration for Improved OSD Development
- Beyond API Sourcing: Avoiding Supply Disruptions For Small Molecule Drugs
PHARMA ONLINE WHITE PAPERS
-
Context-First Data For Trustworthy AI In Biopharma
Bridge the gap between AI experimentation and enterprise value. Learn how capturing structured, semantically rich data at the point of origin builds regulator-credible AI pipelines.
-
A Simple And Powerful Solution For Accelerating Dissolution5/5/2026
Many poorly soluble drugs fail not because of low solubility, but because they dissolve too slowly. Learn how focusing on dissolution rate can unlock absorption gains using simple strategies.
-
Patented Process For Olopatadine HCl API Intermediates7/15/2026
See how this patented Wittig-based process for olopatadine HCl achieves Z/E isomer ratios up to 4:1, eliminating dangerous reagents like n-butyl lithium while cutting purification complexity.
-
Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds5/6/2026
Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.
-
Flexible Fill/Finish Solutions To Bridge The Clinical-To-Commercial Gap7/23/2025
As biopharma complexity grows, flexible CDMOs are essential for navigating evolving fill/finish needs, accelerated timelines, and regulatory uncertainty with agility and expertise.
-
High-Dose Delivery: Integration And Performance8/12/2026
High-viscosity therapies bring new delivery challenges. Explore how needle, syringe, and device design affect injection performance, reliability, and user experience.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 10.31.26 -- Aseptic Contract Manufacturing Services
- 10.30.26 -- Software Solutions To Streamline Pharmaceutical Operations
- 10.30.26 -- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- 10.30.26 -- What's Being Overlooked In Biopharma Manufacturing?
- 10.29.26 -- Early Developability Assessment Reduces Risk In Multi-Specific Antibody Programs
- Modulus Brings Home Top Award At 2026 FOYAs
- Designing Pharma Facilities For Change, Not Just Capacity
- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- Capturing Tablet Disintegration for Improved OSD Development
INDUSTRY NEWS
-
Let Your Voice Help Shape Pharma Manufacturing
Pharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
-
ISPE Announces 2026 FOYA Winners
These awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
Høeg In, Pazdur Out At The FDA
What an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
EDITORIAL COLLECTIONS
Our curated Editorial Collections bring expert insights together in one place, offering practical perspectives and actionable guidance to help you navigate complex decisions and improve performance.
More Editorial CollectionsSUPPLIER NEWS
-
Lonza Further Expands Bioconjugation Manufacturing To Support Growing ADC Demand10/29/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the further expansion of its integrated bioconjugation manufacturing offering. Lonza is combining the flexibility of mid-scale bioconjugation manufacturing with its previously announced large-scale bioconjugation expansion in Visp (CH), which will now include three multiproduct suites. Together, these capabilities will offer customers a scalable manufacturing pathway from clinical development through commercial supply for antibody-drug conjugates (ADCs) and other bioconjugates.
-
Ardena Launches Online Biomarker Catalogue: 228 Markers, One Quote Request10/29/2026
Ardena has launched a searchable Biomarker Catalogue on its website, giving sponsors a faster route from biomarker selection to a bioanalysis quote.
-
Meissner Hosts Ribbon Cutting Ceremony For X-Ray Irradiation Services And Breaks Ground On Phase 2 Of Its Athens, Georgia, U.S.A. Campus10/23/2026
Meissner Corporation, a leading manufacturer of advanced microfiltration and therapeutic manufacturing systems for biopharmaceutical production of life-saving and life enhancing medicines, celebrated a double milestone in Athens-Clarke County: the ribbon cutting for its new X-ray irradiation services facility and the groundbreaking for Phase 2 of its Athens, Georgia, U.S.A., manufacturing campus.
-
Global Pharma Manufacturing Community Meets In Berlin For PHARMAP 202710/22/2026
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027 to address the growing disconnect between investment and outcomes. The closed-door format, supported by Host Sponsor Bayer AG, fosters direct dialogue between pharmaceutical companies, contract manufacturing organisations and service providers, creating space for ongoing discussions that move beyond theory and deliver actionable solutions.
-
LGM Pharma Acquires Sannova Analytical, Expanding cGMP Analytical And GLP Bioanalytical Services10/22/2026
LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and drug development services, today announced it has acquired Sannova Analytical, a contract research laboratory headquartered in Somerset, N.J. The acquisition expands LGM Pharma’s analytical testing services business by adding Good Laboratory Practice (GLP) bioanalysis, including peptide and oligonucleotide testing, and by bringing genotoxic and nitrosamine impurity testing, extractables and leachables evaluations, and additional elemental impurities testing to LGM Pharma’s existing cGMP analytical services. Sannova will continue to operate under its own name as Sannova Analytical, led by its current management team.

